Mindset Pharma Inc (fka MSSTF)

[Renee]

MSSTF: Pursuant to the terms and conditions of the Arrangement Agreement, all holders of outstanding Common Shares are entitled to receive CA$0.75 in cash for each Common Share held.

FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[BubbaInSC]

msstf flying under radar?

[BubbaInSC]

pps broke below 50 day MA

[bell345]

https://biotechinvestmentnews.com/?utm_campaign=mndst_nwlg_ml&utm_medium=print&utm_source=mglg_nwslg&utm_content=msstf_pharma_hlth_cr_lf_sc_wstch



they sent me the brochure in snail mail

[BubbaInSC]

Move To Upside??

[BubbaInSC]

Mindset_Files_International_Patent_Application_for_its_Novel_Psilocybin_Synthesis_Method

8/3/21
https://www.globenewswire.com/news-release/2021/08/03/2273666/0/en/Mindset-Files-International-Patent-Application-for-its-Novel-Psilocybin-Synthesis-Method.html

TORONTO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE:9DF) (OTCQB:MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and neuropsychiatric disorders with unmet medical needs, today announced that it has filed an international patent application for its novel psilocybin synthesis method. The application claims the priority date of the Company’s previously filed United States Patent and Trade Office provisional application, filed on July 24, 2020.

The patent application covers Mindset’s Synthesis Process, a ground-breaking process to synthesize psilocybin and psilocin—two of the known active compounds in psychedelic mushrooms. This process enables faster psilocin and psilocybin synthesis compared to many of the established methodologies used today and has advantages over current processes that include: lower cost, milder reaction conditions, more convenient operations, easily obtained commercially available raw materials, suitability for multi-kilogram scale manufacturing, and lower environmental impact.

Malik Slassi, Mindset’s VP of Innovation commented, “Since filing our provisional patent application in July of 2020, we have made substantial progress towards demonstrating the commercial viability of our synthesis process. Earlier this year, we engaged a leading international contract development and manufacturing organization ("CDMO") to complete optimization and scale-up of the process. To date, significant optimization work has been completed and we are now initiating a 100g pilot scale synthesis to be followed by a 1.0 kg batch of cGMP psilocybin using Mindset's Synthesis Process. The large-scale cGMP synthesis batch is expected to be completed by the end of 2021.”

“We believe that our proprietary synthesis process is likely the most cost-effective method available in the marketplace today for cGMP grade psilocybin. The process strategically complements our next generation drug development programs and represents a significant potential market opportunity with near-term revenue potential. We anticipate that there will be significant demand for our cGMP psilocybin supply given the increasing number of trials and studies underway utilizing psilocybin,” added James Lanthier, CEO of Mindset.

[BubbaInSC]

Nice Break Above Resistance of 0.55

Still think there's some room for short term run up.

Next level of resistance will be 0.70ish

[BubbaInSC]

MSSTF_is_on_schedule_to_produce_1Kilo_of_Pharma_Grade_Psilocybin_by_CY21Q4

I agree with you. MSSTF should have no problems selling if they can keep their production deadline

[Clonemaster]

Patents are great but a legal nightmare and financial burden to pursue actions against foreign companies. I'd like to see them bring in some revenue and this stock will start lighting up screens.

[BubbaInSC]

Am Most Interested in Patents for Production of more effective/safer psychedelic compounds

Others will need to get the pure pharma grade compounds from someone - why not MSSTF?

I am researching this company so far very interesting.

[Clonemaster]

I am researching this company so far very interesting.

[BubbaInSC]

Superior_Efficacy_and_Improved_Safety_in_Head-to-Head_Comparison_to_Psilocybin_for_its_lead_MSP-1014

7/7/21

https://www.globenewswire.com/news-release/2021/07/07/2258857/0/en/Mindset-Pharma-Announces-Additional-Preclinical-Results-Suggesting-Superior-Efficacy-and-Improved-Safety-in-Head-to-Head-Comparison-to-Psilocybin-for-its-First-Lead-Clinical-Candid.html

Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014
--
MSP-1014, a next generation psychedelic medicine showed superior 5-HT2A receptor efficacy and safety compared to psilocybin
--
TORONTO, July 7, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and neuropsychiatric disorders with unmet medical needs, today announced that its first lead clinical candidate, MSP-1014, a differentiated next-generation psilocybin drug candidate from its Family 1 of novel, patent-pending psychedelic compounds, has further demonstrated superior efficacy and an improved safety profile in head-to-head pre-clinical comparisons to psilocybin.

“There is a growing body of supporting evidence that suggests MSP-1014 will deliver superior efficacy and an improved safety profile compared to generic psilocybin,” said Joseph Araujo, Chief Scientific Officer of Mindset. “One critical pre-clinical study we used to assess MSP-1014’s potential superior efficacy compared to psilocybin was 5-HT2A receptor activity. 5-HT2A is a serotonin subtype receptor well understood to be highly correlated with a psychedelic experience. To assess this activity, we compared MSP-1014 to psilocybin using the mouse head twitch response (HTR) assay. We observed an increased number of HTRs, indicated by sequences of rapid head shakes or twitches, following 3 mg/kg doses of MSP-1014 compared to psilocybin. With equimolar doses of psilocybin and MSP-1014, MSP-1014 more than doubled HTRs in mice. When compared to psilocybin, locomotor activity was not reduced with increased doses of MSP-1014 in mice. These findings were confirmed in rats, in which MSP-1014 showed wet dog shakes and back muscle contractions (WDS/BMC) equal to or greater than psilocybin. Additionally, increasing doses of MSP-1014 did not result in body temperature reduction, which is seen when administering increasing doses of psilocybin.”

“We believe the superior traits of MSP-1014 have the potential to provide a safer and more scalable alternative in the world of psychedelic medicine, with the potential to treat a broad range of neuropsychiatric disorders,” said James Lanthier, CEO of Mindset. “MSP-1014 is just the beginning for Mindset. Mindset has developed and continues to grow a broad and diverse pipeline of improved and differentiated second and third generation psychedelic medicines with the goal of creating improved psychedelic therapeutics. We look forward to announcing additional results and milestones from our new drug program soon.”

About MSP-1014

MSP-1014 is a differentiated psilocybin-based compound from Mindset’s Family 1 of novel, patent-pending psychedelic compounds. MSP-1014 was the first compound identified by the Company to progress towards human clinical trials after displaying high rates of success through a comprehensive range of specialized in vitro and in vivo tests.

For additional detail on our Family 1 lead candidate MSP-1014, please watch the following interview from Mindset’s management team:

.

About Mindset Pharma Inc.

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is advancing its own proprietary therapeutics identified across its four novel families of psychedelic-inspired compounds.

[BubbaInSC]

MSSTF_is_producing_Pharma_Grade_Psilocybin_California_advances_decriminalizing_psychedelic_substances


6/29/21
https://apnews.com/article/california-health-government-and-politics-c3eb439025f5f0b50090c73f22183cd0

SACRAMENTO, Calif. (AP) — California on Tuesday moved another step closer to decriminalizing psychedelics — amid a debate over whether their prohibition is an outdated remnant of the War on Drugs — after the author removed a substance from the bill that opponents said can be used as a date-rape drug.

The bill would allow those 21 and older to possess for personal use and “social sharing” psilocybin, the hallucinogenic component of so-called magic mushrooms. It also covers psilocyn, dimethyltryptamine (DMT), ibogaine, mescaline excluding peyote, lysergic acid diethylamide (LSD) and 3,4-methylenedioxymethamphetamine (MDMA, often called ecstasy).

“People’s lives are literally transformed because of these substances,” said Sen. Scott Wiener, a Democrat from San Francisco, though he amended his bill to remove ketamine from the list.


Keeping the potential date-rape drug “would have just confused what you ultimately want to get accomplished,” said the Assembly Public Safety Committee’s chairman, Democratic Assemblyman Reggie Jones-Sawyer, who otherwise supported the bill.

Psychedelics have emerged as “an extremely promising approach to a variety of mental illnesses,” testified Dr. Robert Grant, who studies ketamine-assisted psychotherapy for depression and anxiety at the University of California, San Francisco, which is creating a research center in August to study their use. “Certainly people should not be incarcerated for seeking a healing path with these medications.”

The bill bars sharing with those under age 21 or possessing the substances on school grounds. It would remove the state’s ban on cultivating or transferring mushroom spores or other material containing psilocybin or psilocyn.

Even if California makes the bill law, the drugs would still be illegal under federal law.

It cleared the Assembly Public Safety Committee, 5-3, with proponents touting the benefits to military veterans and others they say can benefit from the use of psychedelics to treat trauma. The measure already passed the state Senate on a 21-16 vote and now heads to the health committee before it can go to the full Assembly.

“Having tried all that was offered to me by military medicine, I was barely holding on. I turned to psychedelics as a last-ditch effort to survive, and fortunately it worked amazingly well,” testified Jesse Gould, the founder and president of the Heroic Hearts Project who served three combat tours as an Army Ranger.

Oregon voters last year approved decriminalizing small amounts of psychedelics among other drugs, and separately were the first to approve the supervised use of psilocybin in a therapeutic setting.


Oakland and Santa Cruz are among cities including Washington, D.C.; Ann Arbor, Michigan; and Somerville and Cambridge, Massachusetts, that have decriminalized certain natural psychedelics that come from plants and fungi. Denver was the first U.S. city to decriminalize hallucinogenic mushrooms for personal use two years ago.

California Narcotics Officers Association legislative director John Lovell said the organization doesn’t seek to incarcerate anyone for drug use.

But he told the committee that the bill’s allowance of social sharing could bring more overdoses and fatalities from contaminated drugs, and LSD should be excluded because “it is married to flashbacks” and can result in “a trip people can have for the rest of their lives.”

Even with the removal of ketamine, “there are still many dangerous, illegal drugs” on the list that lack approval by the U.S. Food and Drug Administration, said Frank Lee, president of the Organization for Justice and Equality. Moreover, he said, allowing for social sharing is “effectively giving the drug dealers a built-in defense.”

Republican Assemblyman Kelly Seyarto said he favors anything that helps veterans, but “it has to be done in a clinical setting, it has to be done under the watchful eye of a physician” to make sure there are no ill effects.

Under Wiener’s bill, he said, “this will be just like beer, you just go get the 21-year-old to give you the stuff.”

Wiener cited studies by Johns Hopkins University, the University of California, San Francisco and UCLA that found psychedelic therapies can help where other treatments have failed. He said other research has shown the use of MDMA can help reduce the severity of post-traumatic stress disorder.

His bill would require the California Department of Public Health to create a working group to study the regulation and use of the drugs and make recommendations to lawmakers.

But his bill goes beyond allowing only therapeutic use. He argued the broader lifting of penalties is another step away from penalizing nonviolent drug offenses and what Wiener called the failed policies of the 50-year War on Drugs that have ”made us less safe because people use in the shadows.”

“It’s time we acknowledge the benefits of these substances even outside of a clinical study,” Wiener said. Opposition to legalizing the drugs “is like the psychedelic equivalent of ‘Reefer Madness,’ that this is going to do all sorts of horrible things. And that is just not true.”

Among other things, his bill would repeal provisions in state law saying that messages from state drug and alcohol programs should promote abstaining from the unlawful use of any drugs or alcohol.

[BubbaInSC]

Mindset_Announce_Availability_of_First_Preclinical_Psychedelic_Benchmark_Data_from_COPE_Program

Toronto, Ontario-- June 14, 2021 - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, and InterVivo Solutions (“InterVivo”), today announced the availability of their first data set as part of the Cooperative Psychedelics Evaluation Platform (“COPE”) program. The COPE program, launched in March, aims to create the world’s first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including psilocybin, LSD, DMT, and 5-MeO-DMT, amongst others. COPE data is available to InterVivo sponsors via a partnership between Mindset and InterVivo that will allow all parties to benefit from the use of COPE data.

The preliminary data focuses on psilocybin/psilocin and demonstrates that the clinical exposure levels reported in humans correlates well to exposure and efficacy measures observed in mice – validating the predictive value of InterVivo’s selected behavioral assays and animal models. Assuming these relationships apply to other reference psychedelics, this data should enable back translation of human clinical study data to InterVivo’s behavioral model platform.

“A founding principal of Mindset has been to continuously assemble comprehensive data on both our own novel drugs, as well as reference compounds, to guide and inform our scientific decision making. The COPE program data sets have been carefully built in partnership with InterVivo’s industry leading pre-clinical scientific team. We believe that this data will be of great use to in the broader psychedelic / CNS space. With InterVivo we are developing the tools and metrics with which the industry can benchmark success of new drugs. We’re delighted with the progress and insights driving the efficiency of our drug development engine and are eager to translate that knowledge into real value for the mental health crisis we aim to solve,” commented James Lanthier, CEO of Mindset.

Dr. Guy Higgins, Ph.D., Chief Scientific Officer of InterVivo and a Scientific Advisory Board member of Mindset, commented. “Despite the widespread interest in the therapeutic potential of psychedelics, there is relatively little preclinical data relating their efficacy/safety profiles and how these relate to plasma and CNS exposures, and PK property. Developing this knowledge base for psychedelics such as LSD and psilocybin, currently being evaluated in the clinic, will undoubtedly help the value assessment of newer psychedelics in development. This requires significant expertise in bioanalysis and pharmacokinetics, and we are fortunate to have the expertise and leadership of Drs. Inés de Lannoy and Lilia Magomedova to lead this research.”

[BubbaInSC]

6/3/21_MSSTF_picks_psilocybin-based_compound_MSP-1014_as_lead_clinical_candidate

MSSTF is projected to have lab-grade/Pharma-Grade psilocybin compounds available this fall. All these other psilocybin/psychedelic pennies are gonna need compounds from someone. Why not MSSTF?

MSSTF will hopefully start generating revenues later in CY21 - and is 2-3 years AHEAD of other companies - that are still going thru clinical trials where actual revenues are still 2-3 years away.

6/3/21
https://seekingalpha.com/news/3702844-mindset-pharma-picks-psilocybin-based-compound-msp-1014-as-lead-clinical-candidate

6/5/21

Mindset Pharma (OTCQB:MSSTF) has selected its lead clinical candidate, MSP-1014, a differentiated psilocybin-based compound to move forward into current good manufacturing practice ((cGMP)) compliant manufacturing and investigational new drug (IND)-enabling studies.
MSP-1014 has the potential to be a safer, more efficacious analog to psilocybin, with reduced potential side effects, the company said.
The company anticipates MSP-1014 to have the potential to treat mood disorders, including major depressive disorder, substance misuse disorders and end-of-life angst associated with terminal illnesses, including cancer.
MSP-1014 demonstrates superior preclinical characteristics in head-to-head comparison with psilocybin and its active metabolite psilocin, including increased safety and efficacy.

2/21/21 Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process
https://finance.yahoo.com/news/mindset-pharma-reaches-agreement-manufacture-120000151.html

[BubbaInSC]

4/29/21_Mindset_Pharma_Announces_Positive_Preclinical_Results_of_Its_Proprietary_Next_Generation_DMT_&_5-MeO-DMT_Compounds

https://www.biospace.com/article/mindset-pharma-announces-positive-preclinical-results-of-its-proprietary-next-generation-dmt-and-5-meo-dmt-compounds/

Published: Apr 29, 2021

Toronto, Ontario--(Newsfile Corp. - April 29, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that certain of Mindset's Family 4 compounds, a group of patent-pending novel chemical entities that are inspired by DMT & 5-MeO-DMT, are exhibiting positive in vitro screening characteristics.

James Lanthier, CEO of Mindset, commented, "N,N-dimethyltryptamine (DMT) & 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) are potent, short-acting psychedelic drugs that produce strong hallucinogenic effects. DMT & 5-MeO-DMT are attracting growing attention as potential therapeutics for neuropsychiatric indications. The depth of psychedelic experience that these drugs induce coupled with their relatively short duration of action make them desirable candidates for in-clinic treatment models. DMT & 5-MeO-DMT analogs, optimized for reduced toxicity and improved pharmacokinetic and pharmacodynamic characteristics, could have considerable potential as next generation psychedelic medicines.

We are pleased to report that a number of proprietary Mindset's Family 4 compounds, in particular those which aim to improve on the efficacy and safety profiles of 5-MeO-DMT, are exhibiting comparable functional and binding in vitro effects, and in some cases superior, agonist properties across key human serotonin receptor subtypes expressed in the central nervous system ("CNS"). These include not only the 5-HT2A receptor subtype, which is well understood to be highly correlated with a psychedelic experience, but also the 5-HT1A and 5-HT2C receptors as well. Published data has suggested that activation of the 5-HT1A as well as 5-HT2C receptors may also play a significant role in contributing to the subjective and behavioral effects implicated in depression, anxiety, mood regulation, substance misuse and eating disorders, among other CNS disorders, elicited by psychedelics.

Mindset has also completed in vitro absorption, distribution, metabolism and excretion profiling on a subset of the compounds from Family 4 and as expected, several compounds demonstrated relatively short durations of action compared to other classic psychedelics.

These results are highly promising, and Mindset will continue to evaluate and advance its Family 4 compounds, both in vitro and in vivo, alongside several promising compounds from its other novel compound families. Mindset's proprietary next-generation psychedelic drug pipeline continues to expand and we will provide updates of such expansion at the appropriate time."

[BubbaInSC]

MSSTF_Has_Agreement_To_Produce_Pharma_Grade_Psilocybin_Using_Patented_Process

Other companies in this space will need access to pharma grade psilocybin.

It has to come from somewhere/someone.

Might as well be MSSTF



Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process
https://www.biospace.com/article/mindset-pharma-reaches-agreement-to-manufacture-large-quantity-of-pharmaceutical-grade-psilocybin-using-patent-pending-synthesis-process/

Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has engaged a leading international contract development and manufacturing organization ("CDMO") to synthesize a 1.0 kg batch of cGMP (i.e. pharmaceutical grade) psilocybin utilizing Mindset's innovative and cost-effective patent-pending synthesis process. The large scale cGMP synthesis batch is expected to be released in the fall of 2021.

Mindset anticipates that there will be significant demand for its proprietary, high-quality psilocybin supply given the increasing number of trials and studies underway utilizing psilocybin. High-quality psilocybin for clinical research purposes is currently expensive and difficult to procure, however Mindset's cost-effective patent-pending synthesis process provides Mindset with a unique advantage to accelerate the commercialization of its portfolio of intellectual property. Several CDMOs that specialize in psilocybin synthesis have exclusive relationships with individual clients, further narrowing the range of psilocybin supply options. Additionally, Mindset is not aware of any existing psilocybin suppliers that have synthesized a commercial quantity at a scale exceeding 1.0kg.

James Lanthier, Chief Executive Officer of Mindset, commented, "We believe that Mindset's proprietary synthesis process can benefit the entire medical psychedelic market, from the drug design process stage to clinical treatment as it is scalable, efficient, and, to our knowledge, one of the most cost-effective methods available in the marketplace today for GMP grade psilocybin, with a non-optimized cost per gram substantially below current retail costs.

"Mindset's synthesis process strategically complements our next generation drug development programs and represents a significant potential market opportunity. Mindset's novel synthesis process meets an increasing need from the growing medical psychedelic space for a reliable source of affordable, pharmaceutical grade psilocybin. We anticipate even further refinements to our process that will enable us to significantly improve cost and efficiency."

Joseph Araujo, Chief Scientific Officer, Founder and Director, commented, "The excitement and enthusiasm demonstrated by this world class CDMO has given us further confidence that this process is potentially game-changing for the industry and should enhance access to psychedelic-assisted treatments for people with the greatest needs. We already have had multiple supply enquiries, as has the CDMO, and we are confident that demand for our synthetic psilocybin will be robust."

[Magnum7419]

Serious manipulation of share price IMHO

https://ih.advfn.com/stock-market/USOTC/mindset-pharma-qb-MSSTF/trades

[Magnum7419]

"pursuant to which the Lead Underwriter has agreed, on behalf of a syndicate of underwriters (together with the Lead Underwriter, the "Underwriters"), to purchase, on a "bought deal" basis pursuant to the filing of a short form prospectus, an aggregate of 6,670,000 units of the Company (each, a "Unit") at a price of $0.75 per Unit (the "Issue Price") for aggregate gross proceeds to the Company of $5,002,500 (the "Offering"

https://www.mindsetpharma.com/news/mindset-pharma-announces-5-million-bought-deal-financing

[Magnum7419]

"Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform ("Cope")

https://www.mindsetpharma.com/news/mindset-pharma-and-intervivo-solutions-to-jointly-develop-advanced-cooperative-psychedelics-evaluation-platform-cope-cope-expected-to-be-worlds-first-in-vivo-psychedelic-benchmark-data-set

[Magnum7419]

$MSSTF Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development

https://www.mindsetpharma.com/news/mindset-pharma-expands-scientific-team-dr-malik-slassi-appointed-senior-vp-innovation-and-ian-dean-appointed-director-preclinical-development

[Magnum7419]

Reminds me of when I discovered KUSH :)

[Magnum7419]

Hard to believe no one knows about this company.